Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Following Pfizer's acquisition, Biohaven's valuation surged from $300M at $7/share to over $4B at $42/share under Vlad Coric's leadership. Despite the significant valuation increase, substantial ...

Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary made improper payments to physicians to boost sales of its migraine ...

Pfizer has beaten Wall Street's revenue estimate ... including through the acquisition of Seagen and Biohaven Pharmaceuticals, which allowed it to rejuvenate its cancer and neuroscience franchises.

For Pfizer Inc., the strategy has been “go big ... the deals included the $11.6 billion acquisition of migraine drug maker Biohaven Pharmaceutical Holding Co. Ltd and the $5.4 billion ...

Biohaven meanwhile recorded Nurtec ODT sales of $462 million in 2021, a performance that prompted Pfizer to stump up $500 million upfront for rights to the drug outside the US last November.

A coalition of the U.S. Department of Justice, 37 states, and Puerto Rico, filed suit against Biohaven Pharmaceutical Holding Company, a subsidiary owned by Pfizer. Pfizer has agreed to pay $ ...

Existing research indicates that the accuracy of a Parkinson’s disease diagnosis hovers between 55% and 78% in the first five years of assessment. That’s partly because Parkinson’s sibling movement ...

Biohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint in a pivotal Phase II/III bipolar trial, sinking the company’s stock price. The US-based biotech shared the announcement as ...